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Introduction
Experimental Procedures
Results
1. Bitter melon extract (BME) dose dependently exerts cytotoxic effect on MCF-7 cells .
2. BME decreases glucose clearance from the medium possibly 
due to less number of viable cells remaining in BME treated cultures.
3.   ROK inhibitor, H-1152, seems to increase viability of MCF-7 cells (non-significant). 
4. Protein kinase C does not affect viability of MCF-7 cells.          
1.Measure the changes in phosphorylation of ROK target protein, MYPT1, and that of PKC 
target protein, CPI-17, with bitter melon extract treatment.
2.Measure the change in phosphorylation of Myosin Light Chain with bitter melon extract 
treatment.
3.Measure cytotoxicity induced by bitter melon extract using Lactate Dehydrogenase (LDH) 
and MTT assays which are more specific than Trypan Blue exclusion assay that we 
performed.
Conclusions
Bitter melon is known to enhance uptake of glucose 
and lipid by healthy cells, and it is also known to inhibit 
growth of cancer cells [1,2,3]. However, the effects of 
bitter melon extract (BME) for inhibiting uncontrolled 
division of cancer cells depend on the types of cancer 
cells. Since breast cancer is one of the most common 
cancers in women [4], breast cancer cell line (MCF-7 
cells) has been chosen in this project to investigate 
the effects of BME. 
Rho Kinase (ROK) and Protein Kinase C (PKC) are 
critically involved in cell division, cell migration, and 
cell survival [5,6] (Figure 1). ROK phosphorylates 
MYPT1 [Myosin targeting subunit of myosin light chain 
phosphatase (MLCP)] and inhibits MLCP. PKC 
phosphorylates CPI-17 which then binds with MLCP 
and inhibits it. Thus, ROK and PKC both inhibit MLCP 
activity favoring balance tilt towards enhanced 
myosin light chain kinase (MLCK) activity which 
then phosphorylates myosin light chain (MLC). 
Phosphorylated MLC activates actin-myosin cross 
bridge formation which in  turn regulates cellular 
processes such as cell migration, cell division, and 
cell survival. 
However, roles of ROK and PKC inhibition on MCF-7 
cells have not been established. In addition, whether 
the effects of BME are mediated by ROK or PKC are 
unknown. Thus, we aimed to investigate if BME exerts 
cytotoxic effects on breast cancer cells (MCF-7 cells) 
and if PKC and ROK mediate BME’s effects.
Bitter melon extract (BME) dose-dependently exerts cytotoxic effect on MCF-7 cells.
Equal number of MCF-7 cells was cultured for 4 days in all the flasks and followed by washing in 1X PBS, pictures of cultures were taken at 40X magnification.
Figure 4. BME dose-dependently decreases glucose 
clearance from culture medium
After 4 days of culture, glucose in the medium was measured by glucose meter (Bio Reactor Sciences GF-100)
Figure 3.  BME dose-dependently decreases the number of MCF-7 cells adhered to the culture flasks
Figure 6. BME dose-dependently decreases 
viability of MCF-7 cells
Cell viability was determined with Trypan Blue
dye using hemocytometer.
Rho kinase (ROK) inhibition potentiates BME’s cytotoxic effect on MCF-7 cells.
Equal number of MCF-7 cells was cultured in all the flasks for 2 days followed by washing in 1X PBS, 
pictures of cultures were taken at 40X magnification.
References
1. Making bitter melon extract (BME)
Fresh bitter melons were purchased from an Asian grocery store. The
y were washed and ground in a juice extractor. The juice extract was 
centrifuged at 5000 RPM/15 minute/9 times and filter sterilized. BME 
aliquots were stored at -80°C.
2. Dose-response effects of BME
Equal number of MCF-7 cells were plated in 250 mL culture flasks con
taining DMEM medium and increasing amount of BME [0%, 0.5%, 1%
, 2%, 5%, and 10% of BME (v/v)].  
3. Testing roles of Rho kinase (ROK) 
and protein kinase C (PKC) inhibitors
To study whether PKC or ROK play any in mediating BME’s effects, e
qual number of MCF-7 cells were cultured in 100 mL culture flasks co
ntaining DMEM medium in the following conditions; 0% BME, 1% BM
E, PKC inhibitor (GF109203x; 0.5µM)/ ROK inhibitor (H-1152; 1 µM), 
and one of the inhibitors combined with 1% BME. 
4. Taking pictures of cultures
After culturing cells for 6 days (for the dose-response study) and 3 da
ys (for the inhibitor studies), pictures of cultures were taken at 5x, 10x, 
and 40x, and cell viability was determined using Trypan blue dye. 
5. Glucose clearance from the medium
After culturing cells for a required number of days, culture was 
centrifuged, clear medium was obtained and remaining glucose in the 
DMEM medium was measured using a glucose monitoring system 
(Bioreactor Sciences).
6. Western Blot
After culturing cells for a required number of days, culture was 
centrifuged and cells were collected, protein was extracted using 
RIPA buffer and proteins candidates of the ROK pathways were 
detected using HRP-conjugated chemiluminescence system.
7. Statistical significance
Repeated t-tests were used to determine statistical significance for 
now. However, with anticipated increased number of observations, 
we plan to use multiple comparison ANOVA. 
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Figure 5. BME dose-dependently prevents drop in 
pH in culture medium suggesting less metabolism
Inhibition of Protein kinase C (PKC) doesn’t affect viability of MCF-7 cells.
Figure 12. PKC inhibitor (GF109203X, 0.5µM) does not affect number of MCF-7 cells adhered to the culture flask
Equal number of MCF-7 cells was cultured in all the flasks for 2 days and followed by washing in 1X PBS, pictures of cultures were taken at 40X magnification.
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Figure 13. PKC inhibitor (GF109203X) does 
not decrease viability of MCF-7 cells
Figure 9. ROK inhibitor (H-1152, 1.0 µM ) seems to 
increase viability of MCF-7. The decreased cell viability 
from combined treatments is likely caused by bitter 
melon extract 
Figure 8. ROK inhibitor (H-1152, 1.0 µM ) increases the number of MCF-7 cells adhered to the culture flask by itself and does not affect  
viability of MCF-7 cells when combined with bitter melon extract
1. Nikambo W., Anyama NG, Onegi B, 2013
2. Nerurkar PV, Lee YK, Nerurkar VR, 2010
3. Ray RB, Raychoudhuri A, Steele R, Nerurkar P, 2010 
4. Serban Comsa, Anca Maria Cimpean, and Marius Raica, 2015
5. AR Black and JD Black, 2013 
6. Sandra Kumper, Faraz K Mardakheh, Afshan McCarthy, Maggie Yeo, et al, 2016
Future directions
Acknowledgement
1. Marian University College of Osteopathic Medicine Biomedical Science Research Fund.
2. Thesis committee members (Drs. Michael Lafontaine, Bilon Khambu, and Medhane Cumbay)
3. Dr. Colleen Doci (Marian University) for providing MCF-7 cells
38Thr
GPCR
ROK
[Ca2+]i
RhoA
Active MLC
Phosphatase
P
MYPT1
Inactive MLC
Phosphatase
MYPT1P
Thr853
Thr696
PKC
CPI-17
CPI-17
P
Bitter Melon 
Extract
Myosin Light Chain 
Kinase activation
Cell division Cell migration Cell viability
Myosin Light Chain
(MLC)
Phospho
Myosin Light Chain
Actin-myosin
Cross bridge
ROK phosphorylates 
MYPT1
PKC phosphorylates 
CPI-17
Figure 1. 
?
? ?
?
0
0.2
0.4
0.6
0.8
1
1.2
no BME 0.50% 1% 2% 5% 10%Vi
ab
le
 C
el
ls
 (%
)
Dose of BME (v/v)
MCF-7 Cell Viability (N=3)
*
*
*
* *
Figure 7. BME dose-dependently 
decreases MYPT1 expression
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Western blot was done with 
sample size of one for three times.
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Figure 10. MYPT1 expression is decreased by BME and ROK inhibitor  
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Figure 11. BME and ROK inhibitor increase MLC20 expression 
Western blot was done with sample size of one for three times.
Cell viability was determined with Trypan Blue
dye using hemocytometer.
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